Abstract:Breast cancer is one of the most common cancers among females and is associated with high mortality and morbidity rates. Several studies have demonstrated that combination treatments with natural products and tamoxifen can improve the sensitivity and cytotoxicity of oestrogen-positive breast cancer cells in response to tamoxifen. Celastrol, a triterpene from traditional Chinese medicine, has been proven to exert significant anticancer effects on various cancers. Our study is aimed at exploring the interactive antitumour effects of celastrol combined with tamoxifen and the potential underlying anticancer mechanisms in MCF-7 cells. The results from MTT assays, isobolographic analyses, and clonogenic cell survival assays revealed that a combination of celastrol and tamoxifen exerted synergistic cytotoxic effects in MCF-7 cells. The results from Annexin V/PI staining and flow cytometry analysis suggested that celastrol enhanced tamoxifen-mediated apoptosis. In addition, exposure to a combination of celastrol and tamoxifen inhibited cell proliferation by causing G1 phase cell cycle arrest. Moreover, the distribution of LC3 was monitored by immunofluorescence, and the changes in the LC3II and P62 levels detected by western blot analysis suggested that celastrol in combination with tamoxifen triggered autophagy. Furthermore, the decrease in p-Akt and p-mTOR in MCF-7 cells, along with the increase in the autophagy marker proteins LC3II and P62, suggested that the Akt/mTOR pathway might be involved in the triggering of cell autophagy by the combination treatment. However, in an MCF-7-implanted nude mouse model, it was possible to detect significantly decreased tumour volumes and tumour weights and decreased p-Akt and p-mTOR protein expression in the celastrol+tamoxifen group. Therefore, our study provides the first evidence that celastrol combined with tamoxifen exerts synergistic anticancer effects by inducing apoptosis and autophagy in MCF-7 cells. Considering the urgent need for novel therapeutic strategies in anticancer therapy, this combinatorial approach is worthy of further investigation.

Celastrol Induces Apoptosis in Non-Small-Cell Lung Cancer A549 Cells Through Activation of Mitochondria- and Fas/Fasl-Mediated Pathways

Celastrol Elicits Antitumor Effects by Inhibiting the STAT3 Pathway Through ROS Accumulation in Non-Small Cell Lung Cancer

Celastrol Inhibits Cancer Metastasis by Suppressing M2-like Polarization of Macrophages.

Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-κB activity.

Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis

ER Stress-Mediated Apoptosis Induced by Celastrol in Cancer Cells and Important Role of Glycogen Synthase Kinase-3Β in the Signal Network

Up-regulation of Death Receptor 4 and 5 by Celastrol Enhances the Anti-Cancer Activity of TRAIL/Apo-2L.

NF-Kappa B Modulation Is Involved in Celastrol Induced Human Multiple Myeloma Cell Apoptosis

Celastrol inhibits mouse B16-F10 melanoma cell survival by regulating the PI3K/AKT/mTOR signaling pathway and repressing HIF-1α expression

Celastrol Induces Apoptosis and Autophagy Via the ROS/JNK Signaling Pathway in Human Osteosarcoma Cells: an in Vitro and in Vivo Study

Celastrol Induces Apoptosis of HT29 Cells through Inhibiting miR-21 Regulation of Bcl-2 Expression

Paraptosis Accompanied by Autophagy and Apoptosis Was Induced by Celastrol, a Natural Compound with Influence on Proteasome, ER Stress and Hsp90.

Beta-catenin mediates the apoptosis induction effect of celastrol in HT29 cells.

The Synergistic Effects of Celastrol in Combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells

Celastrol Acts As a Potent Antimetastatic Agent Targeting Β1 Integrin and Inhibiting Cell-Extracellular Matrix Adhesion, in Part Via the P38 Mitogen-Activated Protein Kinase Pathway

Celastrol impairs tumor growth by modulating the CIP2A-GSK3β-MCL-1 axis in gastric cancer cells

Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells

Celastrol Inhibits Canine Mammary Tumor Cells by Inducing Apoptosis via the Caspase Pathway

Celastrol downregulates E2F1 to induce growth inhibitory effects in hepatocellular carcinoma HepG2 cells.

Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies

Celastrol Prevents Atherosclerosis Via Inhibiting Lox-1 and Oxidative Stress